Mol Cancer Res 2014
Your provider will guide you to the best option based on your medical needs and insurance coverage
This pharmacological profile contributes to its off-label use in managing conditions like anxiety, depression augmentation, and binge eating disorder FDA-Approved and Off-Label Uses FDA-Approved Use: Attention-Deficit/Hyperactivity Disorder (ADHD) in children (age 6+), adolescents, and adults Off-Label Uses: Generalized Anxiety Disorder (GAD) Treatment-resistant depression (as augmentation) Binge Eating Disorder (BED) Obsessive-Compulsive Disorder (OCD) Executive dysfunction in autism spectrum disorders Always consult a licensed medical provider for off-label usage
Nonconventional therapies for Down syndrome: A review and framework for decision making
*Correspondence: Wu Yang, [email protected] Xie, [email protected] This article was submitted to Molecular Signalling and Pathways, a section of the journal Frontiers in Molecular Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
A review of comparisons of semaglutide (Wegovy, Ozempic) to non-GLP-1s in a large EHR database revealed a lower risk of incident and recurrent suicidal ideation among those treated with semaglutide compared to those treated with non-GLP-1 medications
